News + Publications

What’s new at Dispatch

Explore what’s next as we work to expand the curative potential of immunotherapies for solid tumors.

August 6, 2026

Dispatch Bio Announces First Patient Dosed in Phase 1 Study of DISP-10, a Novel Investigational Immunotherapy, in Advanced Gastrointestinal (GI) Cancers

Thu Aug 06 2026

Dispatch Bio Announces First Patient Dosed in Phase 1 Study of DISP-10, a Novel Investigational Immunotherapy, in Advanced Gastrointestinal (GI) Cancers

Mon Apr 27 2026

Dispatch Bio Presents SEND T Cell Armoring Strategy at ASGCT 2026 Annual Meeting

Mon Jan 12 2026

Dispatch Bio and CARsgen Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors

Mon Jan 12 2026

Dispatch Bio Announces FDA Clearance of IND Application for DISP-10, a First-in-Class Immunotherapy Treatment, in Solid Tumors

Tue Nov 04 2025

Dispatch Bio Unveils First Clinical Program and Presents Data Supporting Flare Platform at Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting

Tue Nov 04 2025

Dispatch Bio Announces Clinical Supply and Collaboration Agreement with Bristol Myers Squibb in Solid Tumors

Tue Sep 30 2025

Dispatch Bio Appoints Mauro Avanzi, M.D., Ph.D., as Chief Medical Officer

Fri Sep 19 2025 | Endpoints

Dispatch Bio named to 2025 Endpoints 11 List

Wed Jul 23 2025

News + Publications

What’s new at Dispatch

Dispatch Bio Announces First Patient Dosed in Phase 1 Study of DISP-10, a Novel Investigational Immunotherapy, in Advanced Gastrointestinal (GI) Cancers

Dispatch Bio Presents SEND T Cell Armoring Strategy at ASGCT 2026 Annual Meeting

Dispatch Bio and CARsgen Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors

Dispatch Bio Announces First Patient Dosed in Phase 1 Study of DISP-10, a Novel Investigational Immunotherapy, in Advanced Gastrointestinal (GI) Cancers

Dispatch Bio Presents SEND T Cell Armoring Strategy at ASGCT 2026 Annual Meeting

Dispatch Bio and CARsgen Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors

Dispatch Bio Announces FDA Clearance of IND Application for DISP-10, a First-in-Class Immunotherapy Treatment, in Solid Tumors

Dispatch Bio Unveils First Clinical Program and Presents Data Supporting Flare Platform at Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting

Dispatch Bio Announces Clinical Supply and Collaboration Agreement with Bristol Myers Squibb in Solid Tumors

Dispatch Bio Appoints Mauro Avanzi, M.D., Ph.D., as Chief Medical Officer

Dispatch Bio named to 2025 Endpoints 11 List

Dispatch Bio Launches to Deliver Universal Treatment Across Solid Tumors with Novel Immunotherapy Approach

Connect with Dispatch

News + Publications

What’s new at Dispatch

Dispatch Bio Announces First Patient Dosed in Phase 1 Study of DISP-10, a Novel Investigational Immunotherapy, in Advanced Gastrointestinal (GI) Cancers

Dispatch Bio Announces First Patient Dosed in Phase 1 Study of DISP-10, a Novel Investigational Immunotherapy, in Advanced Gastrointestinal (GI) Cancers

Dispatch Bio Presents SEND T Cell Armoring Strategy at ASGCT 2026 Annual Meeting

Dispatch Bio and CARsgen Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors

Dispatch Bio Announces FDA Clearance of IND Application for DISP-10, a First-in-Class Immunotherapy Treatment, in Solid Tumors

Dispatch Bio Unveils First Clinical Program and Presents Data Supporting Flare Platform at Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting

​​​​​Dispatch Bio Announces Clinical Supply and Collaboration Agreement with Bristol Myers Squibb in Solid Tumors

Dispatch Bio Appoints Mauro Avanzi, M.D., Ph.D., as Chief Medical Officer

Dispatch Bio named to 2025 Endpoints 11 List

Dispatch Bio Launches to Deliver Universal Treatment Across Solid Tumors with Novel Immunotherapy Approach

Connect with Dispatch

Dispatch Bio Announces Clinical Supply and Collaboration Agreement with Bristol Myers Squibb in Solid Tumors